Automatic Website Traffic RSS

Lazard profit beats estimates as dealmaking rebound fuels record revenue

Lazard's first-quarter profit exceeded estimates on Thursday, buoyed by a resurgence in dealmaking at the boutique investment bank. A robust economy and steadying interest rate outlook have sparked a ... read more

Emergence of ADCs as the “hot, new technology”

The cycle from hot to cold to hot again can take 10-15 years and a new technology may go through more than one such cycle (as is evident in the chart above). ADCs are the current “hot thing” in ... read more

Lazard posts better-than-expected profit on deals, assets boost

Lazard's first-quarter profit exceeded estimates on Thursday, buoyed by growth in dealmaking and assets at the boutique investment bank. Growing expectations of interest rate cuts and a flurry of ... read more

Here’s why ImmunityBio (IBRX) stock price surged and what next

ImmunityBio (NASDAQ: IBRX) stock price resumed its strong rally this week after the company achieved a major milestone. After dropping by over 6% in the regular session on Monday, it rebounded by over ... read more

7 Billion-Dollar Oncology M&As from Q1

AbbVie’s $10.1 billion takeover of ImmunoGen paces the cancer sector in early 2024, as ADCs and radiopharmaceuticals remain hot. read more

GSK Sues Pfizer, BioNTech for Share of Billions in Vaccine Sales

GlaxoSmithKline filed a federal lawsuit seeking to recoup a share of the tens of billions of dollars in revenue Pfizer and BioNTech have reported from sales of their Covid-19 vaccines, which GSK ... read more

These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?

Dave has over 13 million registered members, 10 million of whom have used at least one product. It added over 680,000 new members in the fourth quarter. The stock is up 304% in 2024. While it’s not a ... read more

ArriVent Appoints Kristine Peterson to its Board of Directors

“I am excited to work alongside ArriVent’s talented management team and Board of Directors to help address the unmet needs of cancer patients,” said Ms. Peterson. “I look forward to providing ... read more

AbbVie: Great To Be Proven Wrong - Still Not A Buy

AbbVie outperformed expectations, with Humira remaining the market leader with 98% share despite LOE and biosimilar headwinds. Read more on ABBV stock here. read more

AbbVie: Through Humira's Crisis Towards Solid Growth

AbbVie strategically manages patent expiration, fosters innovation, expands pipeline, and enters new markets. Learn more about ABBV stock here. read more

Biosimilar Sales Up as Insurers Begin Dropping Humira Coverage

AbbVie has so far defended its majority market share among biologics for rheumatoid arthritis despite the loss of exclusivity for its flagship drug Humira (adalimumab). But for the first time since ... read more

A drop, a torrent of health

Likewise, a week of recovery is foreseen for infants who cannot attend for different reasons, since the fact that they present symptoms of fever, vomiting or diarrhea, are impediments in the access to ... read more